These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15113990)

  • 1. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity.
    Ibrahim RB; Peres E; Dansey R; Abidi MH; Abella EM; Klein J
    Ann Pharmacother; 2004 Jun; 38(6):1053-9. PubMed ID: 15113990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease.
    Peres E; Kintzel P; Dansey R; Baynes R; Abidi M; Klein J; Ibrahim RB; Abella E
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):203-7. PubMed ID: 18388499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
    Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
    Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
    Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
    Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
    Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
    Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
    Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
    Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation.
    Gordon B; Tarantolo S; Ruby E; Stephens L; Lynch J; Kessinger A; Haire W
    Bone Marrow Transplant; 1998 Nov; 22(10):999-1003. PubMed ID: 9849698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation.
    Haire WD; Ruby EI; Stephens LC; Reed E; Tarantolo SR; Pavletic ZS; Bierman PJ; Bishop M; Kessinger A; Vose J; Armitage JO
    Biol Blood Marrow Transplant; 1998; 4(3):142-50. PubMed ID: 9923412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
    Al Beihany A; Al Omar H; Sahovic E; Chaudhri N; Al Mohareb F; Al Sharif F; Al Zahrani H; Al Shanqeeti A; Seth P; Zaidi S; Morshed M; Al Anazi K; Mohamed G; Gyger M; Aljurf M
    Bone Marrow Transplant; 2008 Feb; 41(3):287-91. PubMed ID: 17982501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK; Wang P; Lee TL; Chiang AK; Ha SY; Lau YL; Chan GC
    Bone Marrow Transplant; 2007 Nov; 40(10):935-44. PubMed ID: 17768390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
    Ho V; Momtaz P; Didas C; Wadleigh M; Richardson P
    Rev Clin Exp Hematol; 2004 Jun; 8(1):E3. PubMed ID: 16029969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?
    Johnson DB; Savani BN
    Exp Hematol; 2012 Jul; 40(7):513-7. PubMed ID: 22542577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
    Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
    Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sinusoidal obstruction disease (SOS), previous hepatic venoocclusive disease (VOD)--still serious complication after hematopoietic stem cell transplantation].
    Gozdzik J; Krasowska-Kwiecień A; Wedrychowicz A
    Przegl Lek; 2008; 65(4):203-8. PubMed ID: 18724548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Veno-occlusive disease in pediatric patients after hematopoietic stem cell transplantation: relevance of activated coagulation and fibrinolysis markers and natural anticoagulants.
    Jevtic D; Zecevic Z; Veljkovic D; Dopsaj V; Radojicic Z; Elezovic I
    J Pediatr Hematol Oncol; 2011 Apr; 33(3):227-34. PubMed ID: 21336167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.